AstraZeneca at 30x Earnings: The Tagrisso Cliff Is What the Pipeline Has to Solve

Important: This article is for educational and informational purposes only. It does not constitute financial advice or a recommendation to buy, sell, or hold any security. Investing involves risk — you may get back less than you invest. If you are unsure whether an investment is right for you, please consult a qualified financial adviser who is authorised by the Financial Conduct Authority (FCA).

AstraZeneca is the FTSE 100's largest company by market capitalisation and one of the better-documented operating turnarounds of the last decade. Under Pascal Soriot, the business has gone from facing one of the steepest patent cliffs in big pharma to running one of the largest oncology pipelines in the industry — and trading at multiples that reflect that. The relevant question for investors in 2026 is not whether the turnaround happened. It is whether the next leg of the pipeline can do the same job for the second half of the decade as Tagrisso has done for the first.

The Openbook Scores

Openbook's scoring model analyses publicly available financial data to produce reward and risk scores on a 0–100 scale. These are model outputs based on historical data and are not investment recommendations.

A higher reward score reflects stronger historical growth, momentum and profitability metrics. A lower risk score reflects a stronger balance sheet and more stable financials. These scores do not predict future performance. AZN's live scores and underlying data are available on the Openbook AstraZeneca page.

The Business as It Stands

AstraZeneca develops and sells prescription medicines across four therapy areas — oncology, rare disease, cardiovascular and respiratory. Oncology is now over 40% of group revenue and the franchise built around Tagrisso (EGFR-mutated lung cancer), Calquence (chronic lymphocytic leukaemia), Enhertu (HER2-positive breast and gastric cancers, developed with Daiichi Sankyo) and Imfinzi (multiple solid-tumour indications) accounts for the bulk of the operating growth. Rare disease, acquired in the 2021 Alexion transaction, has performed in line with the original investment thesis. Cardiovascular and respiratory generate steady cash without contributing much to the headline growth rate.

Geographically, the US is the largest single market and China contributes approximately 12% of revenue — the second-largest single-country exposure and one of the more meaningful emerging-markets pharmaceutical positions held by any large pharma listed outside the country.

What Is Driving the Multiple

AZN trades at roughly 30x forward earnings and 20x trailing revenue. Those multiples are not anomalous against US large-cap quality pharma — Eli Lilly trades higher — but they do require continued operational delivery to justify. The pipeline is the variable that does most of the work. AstraZeneca currently runs over 170 active development projects with more than 20 in late-stage trials, and the strategic direction has been consistent: priorities oncology, expand in rare disease, defend the existing cardiovascular and respiratory franchises against generic erosion.

The most interesting pipeline asset, on consensus, is the further indication expansion of Enhertu. The drug originated as a HER2-positive breast cancer therapy, has expanded into gastric cancer, and the trials reading out across the next 18 months target additional solid tumour types including lung and colorectal. If those readouts support label expansion, Enhertu becomes a multi-billion-dollar revenue line in its own right — large enough to materially offset the headwind from Tagrisso's eventual biosimilar exposure.

What Could Go Wrong

The Tagrisso patent cliff is the single most important catalyst in the AZN equity case, and it is not far away. Tagrisso generated approximately $5.8 billion of revenue in 2025 and is the largest single drug in the portfolio. Biosimilar competition begins to materialise from the late 2020s, with the steepest erosion likely concentrated over a two- to three-year window. Management's stated case is that the pipeline successors — Enhertu indication expansion, Datroway in lung cancer, the rare disease pipeline from Alexion — collectively absorb the Tagrisso decline. The historical track record on managing post-cliff transitions of this size, across the industry, is mixed.

China exposure is the second material risk. The 12% revenue contribution is concentrated in hospital settings where AZN has long-standing relationships, and the company's local commercial infrastructure is the deepest of any Western pharma. That positioning is a structural advantage relative to peers; it is also a concentration of geopolitical risk in a way that does not show up in headline earnings until it does. The relevant comparison here is the 2018 GlaxoSmithKline experience in China, where regulatory action materially affected one quarter of group earnings within a 12-month window.

Currency and FX matter mechanically. AZN reports in USD but the primary share line trades in pence; sustained sterling strength compresses GBP-translated EPS. Most UK investors hold the GBP-listed line, and this exposure is often underweighted in the consensus discussion.

Key Questions to Research Independently

The questions investors typically work through before sizing a position are: whether the current 30x earnings multiple prices appropriate optimism on the pipeline or excessive optimism; how quickly biosimilar competition is likely to materially affect Tagrisso revenue; whether the China exposure is best understood as a competitive moat or a tail risk; and how AZN compares to peers such as GSK (GSK.L) on a risk-adjusted basis given the differences in pipeline composition and geographic exposure.

These are individual judgements that depend on time horizon, return objective and risk tolerance. Openbook's tools provide the data; the position-sizing decision sits with the investor.

Explore AZN's full financial data on Openbook →

This article is produced for educational purposes only and does not constitute a financial promotion, investment advice, or a personal recommendation. Past performance is not a reliable indicator of future results. The value of investments can fall as well as rise and you may get back less than you invest. AstraZeneca scores shown are model outputs based on historical financial data and are not forward-looking predictions. Openbook Analytics is not authorised by the Financial Conduct Authority to provide investment advice.